Tags

Type your tag names separated by a space and hit enter

17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
Vaccine. 2007 Apr 12; 25(15):2758-65.V

Abstract

Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination.

Authors+Show Affiliations

Sealy Centre for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 0609, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Congress
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17368349

Citation

Barrett, Alan D T., et al. "17D Yellow Fever Vaccines: New Insights. a Report of a Workshop Held During the World Congress On Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005." Vaccine, vol. 25, no. 15, 2007, pp. 2758-65.
Barrett AD, Monath TP, Barban V, et al. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007;25(15):2758-65.
Barrett, A. D., Monath, T. P., Barban, V., Niedrig, M., & Teuwen, D. E. (2007). 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine, 25(15), 2758-65.
Barrett AD, et al. 17D Yellow Fever Vaccines: New Insights. a Report of a Workshop Held During the World Congress On Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007 Apr 12;25(15):2758-65. PubMed PMID: 17368349.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. AU - Barrett,Alan D T, AU - Monath,Thomas P, AU - Barban,Veronique, AU - Niedrig,Matthias, AU - Teuwen,Dirk E, Y1 - 2006/12/28/ PY - 2006/09/18/received PY - 2006/11/30/revised PY - 2006/12/05/accepted PY - 2007/3/21/pubmed PY - 2007/9/12/medline PY - 2007/3/21/entrez SP - 2758 EP - 65 JF - Vaccine JO - Vaccine VL - 25 IS - 15 N2 - Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17368349/17D_yellow_fever_vaccines:_new_insights__A_report_of_a_workshop_held_during_the_World_Congress_on_medicine_and_health_in_the_tropics_Marseille_France_Monday_12_September_2005_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(06)01334-X DB - PRIME DP - Unbound Medicine ER -